Neutralization of CD95 Ligand Protects the Liver Against Ischemia-reperfusion Injury and Prevents Acute Liver Failure

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2018 Jan 28

PMID 29374146

Citations 10

Authors

Mohammed Al-Saeedi

Niels Steinebrunner

Hassan Kudsi

Niels Halama

Carolin Mogler

Markus W Buchler

Peter H Krammer

Peter Schemmer

Martina Muller

Affiliations

Soon will be listed here.

Abstract

Ischemia-reperfusion injury is a common pathological process in liver surgery and transplantation, and has considerable impact on the patient outcome and survival. Death receptors are important mediators of ischemia-reperfusion injury, notably the signaling pathways of the death receptor CD95 (Apo-1/Fas) and its corresponding ligand CD95L. This study investigates, for the first time, whether the inhibition of CD95L protects the liver against ischemia-reperfusion injury. Warm ischemia was induced in the median and left liver lobes of C57BL/6 mice for 45 min. CD95Fc, a specific inhibitor of CD95L, was applied prior to ischemia. Hepatic injury was assessed via consecutive measurements of liver serum enzymes, histopathological assessment of apoptosis and necrosis and caspase assays at 3, 6, 12, 18 and 24 h after reperfusion. Serum levels of liver enzymes, as well as characteristic histopathological changes and caspase assays indicated pronounced features of apoptotic and necrotic liver damage 12 and 24 h after ischemia-reperfusion injury. Animals treated with the CD95L-blocker CD95Fc, exhibited a significant reduction in the level of serum liver enzymes and showed both decreased histopathological signs of parenchymal damage and decreased caspase activation. This study demonstrates that inhibition of CD95L with the CD95L-blocker CD95Fc, is effective in protecting mice from liver failure due to ischemia-reperfusion injury of the liver. CD95Fc could therefore emerge as a new pharmacological therapy for liver resection, transplantation surgery and acute liver failure.

Citing Articles

REGγ deficiency ameliorates hepatic ischemia and reperfusion injury in a mitochondrial p66shc dependent manner in mice.

Guo L, Yang Q, Zhu J, Li J Transl Gastroenterol Hepatol. 2024; 9:62.

PMID: 39503032 PMC: 11535816. DOI: 10.21037/tgh-24-46.

Cell Death in Liver Disease and Liver Surgery.

Stoess C, Choi Y, Onyuru J, Friess H, Hoffman H, Hartmann D Biomedicines. 2024; 12(3).

PMID: 38540172 PMC: 10968531. DOI: 10.3390/biomedicines12030559.

Isolation, culture, and delivery considerations for the use of mesenchymal stem cells in potential therapies for acute liver failure.

Yang H, Chen J, Li J Front Immunol. 2023; 14:1243220.

PMID: 37744328 PMC: 10513107. DOI: 10.3389/fimmu.2023.1243220.

Apoptotic cell death in disease-Current understanding of the NCCD 2023.

Vitale I, Pietrocola F, Guilbaud E, Aaronson S, Abrams J, Adam D Cell Death Differ. 2023; 30(5):1097-1154.

PMID: 37100955 PMC: 10130819. DOI: 10.1038/s41418-023-01153-w.

Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations.

Lorente L, Rodriguez S, Sanz P, Gonzalez-Rivero A, Perez-Cejas A, Padilla J World J Clin Cases. 2023; 11(8):1753-1760.

PMID: 36970008 PMC: 10037289. DOI: 10.12998/wjcc.v11.i8.1753.

References

Muller M, Schleithoff E, Stremmel W, Melino G, Krammer P, Schilling T . One, two, three--p53, p63, p73 and chemosensitivity. Drug Resist Updat. 2007; 9(6):288-306. DOI: 10.1016/j.drup.2007.01.001. View

Schilling T, Schleithoff E, Kairat A, Melino G, Stremmel W, Oren M . Active transcription of the human FAS/CD95/TNFRSF6 gene involves the p53 family. Biochem Biophys Res Commun. 2009; 387(2):399-404. DOI: 10.1016/j.bbrc.2009.07.063. View

Gressner O, Schilling T, Lorenz K, Schleithoff E, Koch A, Schulze-Bergkamen H . TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J. 2005; 24(13):2458-71. PMC: 1173149. DOI: 10.1038/sj.emboj.7600708. View

Halama N, Braun M, Kahlert C, Spille A, Quack C, Rahbari N . Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res. 2011; 17(4):678-89. DOI: 10.1158/1078-0432.CCR-10-2173. View

Sun P, Zhang P, Wang P, Zhu L, Du Y, Tian S . Mindin deficiency protects the liver against ischemia/reperfusion injury. J Hepatol. 2015; 63(5):1198-211. DOI: 10.1016/j.jhep.2015.06.033. View

Radi Z, Koza-Taylor P, Bell R, Obert L, Runnels H, Beebe J . Increased serum enzyme levels associated with kupffer cell reduction with no signs of hepatic or skeletal muscle injury. Am J Pathol. 2011; 179(1):240-7. PMC: 3123844. DOI: 10.1016/j.ajpath.2011.03.029. View

Contreras J, Vilatoba M, Eckstein C, Bilbao G, Thompson J, Eckhoff D . Caspase-8 and caspase-3 small interfering RNA decreases ischemia/reperfusion injury to the liver in mice. Surgery. 2004; 136(2):390-400. DOI: 10.1016/j.surg.2004.05.015. View

Spiegel H, Bahde R . Experimental models of temporary normothermic liver ischemia. J Invest Surg. 2006; 19(2):113-23. DOI: 10.1080/08941930600569704. View

Mukhopadhyay A, Ni J, Zhai Y, Yu G, Aggarwal B . Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase. J Biol Chem. 1999; 274(23):15978-81. DOI: 10.1074/jbc.274.23.15978. View

10.

Schattenberg J, Zimmermann T, Worns M, Sprinzl M, Kreft A, Kohl T . Ablation of c-FLIP in hepatocytes enhances death-receptor mediated apoptosis and toxic liver injury in vivo. J Hepatol. 2011; 55(6):1272-80. DOI: 10.1016/j.jhep.2011.03.008. View

11.

Fan C, Zwacka R, Engelhardt J . Therapeutic approaches for ischemia/reperfusion injury in the liver. J Mol Med (Berl). 1999; 77(8):577-92. DOI: 10.1007/s001099900029. View

12.

Liang R, Nickkholgh A, Hoffmann K, Kern M, Schneider H, Sobirey M . Melatonin protects from hepatic reperfusion injury through inhibition of IKK and JNK pathways and modification of cell proliferation. J Pineal Res. 2008; 46(1):8-14. DOI: 10.1111/j.1600-079X.2008.00596.x. View

13.

Peter M, Krammer P . The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 2003; 10(1):26-35. DOI: 10.1038/sj.cdd.4401186. View

14.

Cursio R, Filippa N, Miele C, Colosetti P, Auberger P, Van Obberghen E . Fas ligand expression following normothermic liver ischemia-reperfusion. J Surg Res. 2005; 125(1):30-6. DOI: 10.1016/j.jss.2004.11.026. View

15.

Daemen M, van t Veer C, Denecker G, Heemskerk V, Wolfs T, Clauss M . Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Invest. 1999; 104(5):541-9. PMC: 408540. DOI: 10.1172/JCI6974. View

16.

Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Green D . DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell. 1998; 1(4):543-51. DOI: 10.1016/s1097-2765(00)80054-4. View

17.

Weigand K, Brost S, Steinebrunner N, Buchler M, Schemmer P, Muller M . Ischemia/Reperfusion injury in liver surgery and transplantation: pathophysiology. HPB Surg. 2012; 2012:176723. PMC: 3369424. DOI: 10.1155/2012/176723. View

18.

Malhi H, Gores G, Lemasters J . Apoptosis and necrosis in the liver: a tale of two deaths?. Hepatology. 2006; 43(2 Suppl 1):S31-44. DOI: 10.1002/hep.21062. View

19.

Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M . p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med. 1998; 188(11):2033-45. PMC: 2212386. DOI: 10.1084/jem.188.11.2033. View

20.

Kiener P, Davis P, Rankin B, Klebanoff S, Ledbetter J, Starling G . Human monocytic cells contain high levels of intracellular Fas ligand: rapid release following cellular activation. J Immunol. 1997; 159(4):1594-8. View